A Phase 2a Comparator, Randomized, Open-Label, Study to Assess the Pharmacodynamics, Safety and Pharmacokinetics of Oral Administration MNK6106 (L Ornithine Phenylacetate) vs Rifaximin in Subjects With Hepatic Cirrhosis and a History of Prior Episodes of Hepatic Encephalopathy
Phase of Trial: Phase II
Latest Information Update: 17 Dec 2018
At a glance
- Drugs Ornithine phenylacetate (Primary) ; Rifaximin
- Indications Liver cirrhosis
- Focus Pharmacodynamics
- Sponsors Mallinckrodt Inc.
- 06 Dec 2018 Planned End Date changed from 30 Aug 2019 to 30 Jul 2019.
- 06 Dec 2018 Status changed from not yet recruiting to recruiting.
- 09 Nov 2018 Planned initiation date changed from 15 Nov 2018 to 15 Dec 2018.